BIOA · CIK 0001709941
What BioAge Labs, Inc. told the SEC could break it.
BioAge is a pre-revenue biotech concentrated to a single point on nearly every axis. All of its revenue and accounts receivable come from one customer — its Novartis collaboration — so any change to that agreement would erase its only revenue source, and its pipeline now hinges on a single lead candidate, BGE-102 (its NLRP3 program), after it discontinued former lead azelaprag, making that program's failure highly material. It also has no manufacturing of its own, relying on third-party manufacturers in China and India for its candidates and raw materials; that footprint exposes it to U.S. tariffs and to BIOSECURE-Act-style restrictions on Chinese biotech firms that could disrupt or prohibit its supply.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- single customer = 100% of revenue & receivables (Novartis collaboration)high
BioAge's entire revenue and accounts receivable derive from a single customer (its Novartis collaboration); any change to that agreement would eliminate its only revenue source.
“As of December 31, 2025, one customer accounted for 100 % of the Company's accounts receivable. For the year ended December 31, 2025, the same customer accounted for 100 % of the Company's revenue.”
SEC filing →As of 2026
Other disclosures
- single lead candidate concentration (BGE-102) after azelaprag discontinuationmedium
After discontinuing former lead candidate azelaprag, BioAge's prospects concentrate on its NLRP3 program / BGE-102; failure of that program would be highly material for the pre-revenue company.
“If our development efforts for BGE-102 or other product candidates that we may develop in the future are successful and result in marketing approval, we may generate revenue from product sales.”
SEC filing →As of 2026
Regulatory & policy
- BIOSECURE Act / China trade restrictions & tariffs on CDMOsmedium
Because key manufacturers are in China, BioAge is exposed to U.S. tariffs/trade barriers and to BIOSECURE-Act-style restrictions or sanctions on Chinese biotech firms that could disrupt or prohibit its material supply.
“since some of our third-party manufacturers are located in China and India, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States, such as the recent imposition of tariffs, or other trade barriers, or actions by the Chinese governments, political unrest or unstable economic conditions in China.”
Supplier concentration
- China & India third-party manufacturers (no internal manufacturing)medium
BioAge has no manufacturing facilities and relies on third-party manufacturers located in China and India for product candidates and raw materials for preclinical/clinical and any future commercial supply.
“We do not have any manufacturing facilities, and we currently contract with certain third-party manufacturers, which are located in China and India.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We have recognized, and expect to recognize, collaboration revenue in the future from the Novartis Agreement, which may include amounts related to upfront payments, milestone payments, and research and development funding.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch